abstract |
The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD -L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I- A or Formula I-B, kits comprising the compositions and methods of use therefor. |